Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial

Author(s): Prof Virginie Westeel, MD¹;Pascal Foucher, MD²;Prof Arnaud Scherpereel, MD³;Jean Domas, MD⁴;Jean Trédaniel, MD⁵;Prof Marie Wislez, MD⁶;Patrick Dumont, MD⁷;Prof Elisabeth Quoix, MD⁸;Olivier Raffy, MD⁹;Denis Braun, MD¹⁰;Marc Derollez, MD¹¹;François Goupil, MD¹²;Jacques Hermann, MD¹³;Etienne Devin, MD¹⁴;Hubert Barbieux, MD¹⁵;Eric Pichon, MD¹⁶;Didier Debieuvre, MD¹⁷;Gervais Ozenne, MD¹⁸;Prof Jean-François Muir, MD¹⁸;Stéphanie Dehette, MD¹⁹;Jérôme Virally, MD²⁰;Michel Grivaux, MD²¹;Prof François Lebargy, MD²²;Prof Pierre-Jean Souquet, MD²³;Faraj Al Freijat, MD²⁴;Prof Nicolas Girard, MD²⁵;Emmanuel Courau, MD²⁶;Reza Azarian, MD²⁷;Michel Farny, MD²⁸;Jean-Paul Duhamel, MD²⁹;Alexandra Langlais, MSc³⁰;Franck Morin, MSc³⁰;Bernard Milleron, MD³¹;Prof Gérard Zalcman, MD³²;Prof Fabrice Barlesi, MD³³

Source: DOI: doi.org/10.1016/S1470-2045(22)00451-X

Dr. Anjan Patel's Thoughts

How can you not love these nationalized country studies that make you question foundational oncologic principals; prudence of surveillance CT’s in this case? Thought provoking in the least. No OS or DFS benefit of CT+CXR vs CXR alone! However some benefit was likely present in higher stage groups, and I doubt this will change practice in the US.

BACKGROUND

Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC.

METHODS

In this multicentre, open-label, randomised, phase 3 trial (IFCT-0302), patients aged 18 years or older and after complete resection of pathological stage I–IIIA NSCLC according to the sixth edition of the TNM classification were enrolled within 8 weeks of resection from 122 hospitals and tertiary centres in France. Patients were randomly assigned (1:1) to CT-based follow-up (clinic visits, chest x-rays, thoraco-abdominal CT scans, and fibre-optic bronchoscopy for non-adenocarcinoma histology) or minimal follow-up (visits and chest x-rays) after surgery for NSCLC, by means of a computer-generated sequence using the minimisation method. Procedures were repeated every 6 months for the first 2 years and yearly until 5 years. The primary endpoint was overall survival analysed in the intention-to-treat population. Secondary endpoints, also analysed in the intention-to-treat population, included disease-free survival. This trial is registered with ClinicalTrials.gov, NCT00198341, and is active, but not enrolling.

FINDINGS

Between Jan 3, 2005, and Nov 30, 2012, 1775 patients were enrolled and randomly assigned to a follow-up group (888 patients to the minimal follow-up group; 887 patients to the CT-based follow-up group). Median overall survival was not significantly different between follow-up groups (8·5 years [95% CI 7·4–9·6] in the minimal follow-up group vs 10·3 years [8·1–not reached] in the CT-based follow-up group; adjusted hazard ratio [HR] 0·95, 95% CI 0·83–1·10; log-rank p=0·49). Disease-free survival was not significantly different between follow-up groups (median not reached [95% CI not estimable–not estimable] in the minimal follow-up group vs 4·9 [4·3–not reached] in the CT-based follow-up group; adjusted HR 1·14, 95% CI 0·99–1·30; log-rank p=0·063). Recurrence was detected in 246 (27·7%) of 888 patients in the minimal follow-up group and in 289 (32·6%) patients of 887 in the CT-based follow-up group. Second primary lung cancer was diagnosed in 27 (3·0%) patients in the minimal follow-up group and 40 patients (4·5%) in the CT-based follow-up group. No serious adverse events related to the trial procedures were reported.

INTERPRETATION

The addition of thoracic CT scans during follow-up, which included clinic visits and chest x-rays after surgery, did not result in longer survival among patients with NSCLC. However, it did enable the detection of more cases of early recurrence and second primary lung cancer, which are more amenable to curative-intent treatment, supporting the use of CT-based follow-up, especially in countries where lung cancer screening is already implemented, alongside with other supportive measures.

FUNDING

French Health Ministry, French National Cancer Institute, Weisbrem-Benenson Foundation, La Ligue Nationale Contre Le Cancer, and Lilly Oncology.

Author Affiliations

¹Department of Pneumology, University Hospital of Besançon, INSERM UMR1098, Université de Bourgogne-Franche-Comté, Besançon, France;²Department of Pneumology, University Hospital Bocage, Dijon, France;³University of Lille, CHU Lille, Thoracic Oncology Department, CNRS, Inserm, Institut Pasteur de Lille, UMR9020—UMR-S 1277—Canther, Lille, France ;⁴Department of Pneumology, Institut Curie Montsouris, Paris, France;⁵Department of Pneumology, Saint Joseph Hospital, Paris, France;⁶Pneumology and Thoracic Oncology, Hôpital Tenon, Paris, France;⁷Pneumology Department, Hospital Centre – Chauny, Chauny, France;⁸Pneumology, Nouvel Hôpital Civil – Hôpitaux Universitaires de Strasbourg, Inserm UMR_S 1113, IRFAC, Strasbourg University, Strasbourg, France;⁹Department of Pneumology, Hospital of Chartres, Chartres, France;¹⁰Department of Pneumology, Maillot Hospital, Briey, France;¹¹Department of Pneumology, Maubeuge Hospital, Maubeuge, France;¹²Department of Pneumology, University Hospital of Le Mans, Le Mans, France;¹³Department of Pneumology, Hospital Robert Schuman, Metz, France;¹⁴Department of Pneumology, Hospital of Evreux, Evreux, France;¹⁵Department of Oncology, Hospital of Auxerre, Auxerre, France;¹⁶Department of Pneumology, University Hospital of Tours, Tours, France;¹⁷Department of Pneumology, GHRMSA, Mulhouse, France ;¹⁸Department of Pneumology, University Hospital Rouen Bois-Guillaume, Rouen, France;¹⁹Department of Pneumology, Hospital of Compiegne, Compiegne, France;²⁰Department of Pneumology, Hospital of Aulnay-Sous-Bois, Aulnay-Sous-Bois, France;²¹Department of Pneumology, Hospital of Meaux, Meaux, France;²²Department of Pneumology, University Hospital of Reims, Reims, France;²³Department of Pneumology, Hospital Lyon Sud, Lyon, France;²⁴Department of Pneumology, Hospital of Belfort, Belfort, France;²⁵Pneumology, Hôpital Cardio-Vasculaire and Pneumologique Louis Pradel, Bron, France;²⁶Department of Pneumology, Clinique Pasteur, Toulouse, France;²⁷Department of Pneumology, Hospital of Versailles, Versailles, France;²⁸Pneumology Department, Hospital of Cahors, Cahors, France;²⁹Department of Pneumology, Hospital of Le Havre, Le Havre, France;³⁰Intergroupe Francophone de Cancérologie Thoracique, Paris, France;³¹Pneumology and Thoracic Oncology, Hôpital Tenon, Paris, France;³²Université Paris Cité Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Institut du Cancer, Nord Paris, France;³³Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, CNRS, INSERM, CRCM, APHM, Campus Timone, CHU NORD, Marseille, France

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

The phase III NeoADAURA trial evaluated neoadjuvant osimertinib (OSI) with or without platinum-based chemotherapy (CT) versus CT alone in resectable, EGFR-mutated stage II-IIIB non-small cell lung cancer (NSCLC). Both OSI+CT and OSI monotherapy significantly improved major pathologic response (MPR: 26% and 25% vs 2%), and 12-month event-free survival (EFS) rates were higher with OSI-containing regimens (OSI+CT 93%, OSI 95%, CT 83%). Nodal downstaging was also more frequent with OSI arms (53% vs 21%). Neoadjuvant OSI—with or without CT—looks like a real step forward for our EGFR-mutant NSCLC patients, especially given the robust pathologic responses and high rates of surgical completion.

Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma

This large, well-done study compared systematic mediastinal lymph node dissection (LND) versus no LND in patients with GGO-dominant invasive lung adenocarcinoma (CTR ≤0.5, ≤3 cm, cT1N0M0). Interim analysis of 302 patients showed no lymph node metastases in either arm, with both groups achieving 3-year disease-free survival (DFS) and overall survival (OS) of 100% at the time of analysis. The no LND arm had significantly shorter surgery duration (74 vs 109 min), less blood loss (44 vs 82 mL), shorter hospital stays (3.9 vs 4.5 days), and fewer grade ≥2 complications (3.3% vs 9.3%). Based on these findings, the trial was terminated early for nonmaleficence, and the authors recommend omitting systematic mediastinal LND in this population. In short, for carefully selected GGO-dominant lung adenocarcinoma, skipping mediastinal LND appears safe and spares patients’ unnecessary morbidity—this could be a real practice-changer for our early-stage, node-negative cases.

Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC

The phase 3 MARIPOSA trial compared amivantamab–lazertinib (Ami-Laz) to osimertinib (Osi) in untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC), showing a significant overall survival (OS) benefit for Ami-Laz (3-yr OS was 60% vs 51%). Median OS was not reached for Ami-Laz vs 36.7 months for Osi, with a projected >12-month median OS advantage. Ami-Laz also improved time to symptomatic progression (43.6 vs 29.3 months) and showed durable intracranial control, though grade ≥3 adverse events (AEs) were higher (80% vs 52%), notably skin, venous thromboembolism (VTE), and infusion reactions. In short, Ami-Laz is emerging as a new standard for first-line EGFRm NSCLC, but we’ll need to be proactive about managing its toxicity profile in clinic and whether this is superior or equivalent to Osi + chemo is currently unclear.

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a median progression-free survival (PFS) of 5.5 months compared to 3.8 months with docetaxel in patients with KRAS G12C-mutated tumors. Treatment-related adverse events occurred in 47% of patients receiving Adagrasib and 46% in the docetaxel group. In my experience, Adagrasib is also more tolerable, making it a favorable option for this patient population.

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

There was a 28% reduction in mortality. Patients who achieved a complete response (CR) or clearance of circulating tumor DNA (ctDNA) also experienced better outcomes.